Australia's most trusted
source of pharma news
Thursday, 20 November 2025
Posted 20 November 2025 AM
It's already won a PBAC recommendation and this week Vertex's new cystic fibrosis (CF) drug Alyftrek scored TGA approval, clearing the path for a PBS listing.
Alyftrek has been registered for CF patients aged six and up who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Alyftrek potentiation based on clinical or in vitro assay data.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.